Cargando…

Inhibition of Osteoblast Differentiation by JAK2(V617F) Megakaryocytes Derived From Male Mice With Primary Myelofibrosis

Past studies described interactions between normal megakaryocytes, the platelet precursors, and bone cell precursors in the bone marrow. This relationship has also been studied in context of various mutations associated with increased number of megakaryocytes. The current study is the first to exami...

Descripción completa

Detalles Bibliográficos
Autores principales:	Karagianni, Aikaterini, Matsuura, Shinobu, Gerstenfeld, Louis C., Ravid, Katya
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9307716/ https://www.ncbi.nlm.nih.gov/pubmed/35880162 http://dx.doi.org/10.3389/fonc.2022.929498

Ejemplares similares

Characterization of Glycoproteoforms of Integrins α2 and β1 in Megakaryocytes in the Occurrence of JAK2V617F Mutation-Induced Primary Myelofibrosis
por: Gaye, Maissa M., et al.
Publicado: (2022)

P989: NEWLY IDENTIFIED ROLES FOR PIEZO1 MECHANOSENSOR IN CONTROLLING NORMAL MEGAKARYOCYTE DEVELOPMENT AND IN PRIMARY MYELOFIBROSIS
por: Abbonante, Vittorio, et al.
Publicado: (2023)

JAK2(V617F)-Mediated Clonal Hematopoiesis Accelerates Pathological Remodeling in Murine Heart Failure
por: Sano, Soichi, et al.
Publicado: (2019)

Elevated plasma EDA fibronectin in primary myelofibrosis is determined by high allele burden of JAK2V617F mutation and strongly predicts splenomegaly progression
por: Malara, Alessandro, et al.
Publicado: (2022)

Megakaryocytes Are Regulators of the Tumor Microenvironment and Malignant Hematopoietic Progenitor Cells in Myelofibrosis
por: Varricchio, Lilian, et al.
Publicado: (2022)

JAK2 V617F Genotype Is a Strong Determinant of Blast Transformation in Primary Myelofibrosis
por: Barosi, Giovanni, et al.
Publicado: (2013)

The telomerase inhibitor imetelstat differentially targets JAK2V617F versus CALR mutant myeloproliferative neoplasm cells and inhibits JAK-STAT signaling
por: Olschok, Kathrin, et al.
Publicado: (2023)

Matrix Mechanosensation in the Erythroid and Megakaryocytic Lineages
por: Ward, Christina M., et al.
Publicado: (2020)

JAK2 V617F, MPL, and CALR Mutations in Korean Patients with Essential Thrombocythemia and Primary Myelofibrosis
por: Kim, Bo Hyun, et al.
Publicado: (2015)

Loss of Ezh2 synergizes with JAK2-V617F in initiating myeloproliferative neoplasms and promoting myelofibrosis
por: Shimizu, Takafumi, et al.
Publicado: (2016)

Impact of JAK2V617F Mutational Status on Phenotypic Features in Essential Thrombocythemia and Primary Myelofibrosis
por: Yönal, İpek, et al.
Publicado: (2016)

Shared and Distinctive Ultrastructural Abnormalities Expressed by Megakaryocytes in Bone Marrow and Spleen From Patients With Myelofibrosis
por: Zingariello, Maria, et al.
Publicado: (2020)

Cigarette smoke stimulates clonal expansion of Jak2(V617F) and Tet2(-/-) cells
por: Ramanathan, Gajalakshmi, et al.
Publicado: (2023)

Effect of NS-018, a selective JAK2V617F inhibitor, in a murine model of myelofibrosis
por: Nakaya, Y, et al.
Publicado: (2014)

Is it primary myelofibrosis or chronic megakaryocytic leukemia?
por: Lichtman, Marshall A.
Publicado: (2022)

Loss of wild-type Jak2 allele enhances myeloid cell expansion and accelerates myelofibrosis in Jak2V617F knock-in mice
por: Akada, Hajime, et al.
Publicado: (2014)

Immunoproteasome Genes Are Modulated in CD34(+) JAK2(V617F) Mutated Cells from Primary Myelofibrosis Patients
por: Di Rosa, Michelino, et al.
Publicado: (2020)

Inhibition of interleukin-1β reduces myelofibrosis and osteosclerosis in mice with JAK2-V617F driven myeloproliferative neoplasm
por: Rai, Shivam, et al.
Publicado: (2022)

Increased risk of thrombosis in JAK2 V617F-positive patients with primary myelofibrosis and interaction of the mutation with the IPSS score
por: Barbui, Tiziano, et al.
Publicado: (2022)

JAK2 Exon 14 Skipping in Patients with Primary Myelofibrosis: A Minor Splice Variant Modulated by the JAK2-V617F Allele Burden
por: Catarsi, Paolo, et al.
Publicado: (2015)

Janus Kinase V617F Mutation Detection in Patients with Myelofibrosis
por: Nikolova, D, et al.
Publicado: (2019)

Circulating megakaryocyte in primary myelofibrosis: an uncommon finding in a myelofibrosis blood smear
por: Cantó, Pedro Asensi, et al.
Publicado: (2021)

JAK2 V617F mutation in plasma cell-free DNA preceding clinically overt myelofibrosis: Implications for early diagnosis
por: Choi, Michael Y., et al.
Publicado: (2018)

Neoplastic fibrocytes play an essential role in bone marrow fibrosis in Jak2V617F-induced primary myelofibrosis mice
por: Ozono, Yoshinori, et al.
Publicado: (2020)

Megakaryocytic morphology in Janus kinase 2 V617F positive myeloproliferative neoplasm
por: Ghai, Shuchi, et al.
Publicado: (2017)

Impaired apoptosis of megakaryocytes and bone marrow mononuclear cells in essential thrombocythemia: correlation with JAK2V617F mutational status and cytoreductive therapy
por: Treliński, Jacek, et al.
Publicado: (2012)

IDH mutations in primary myelofibrosis predict leukemic transformation and shortened survival: clinical evidence for leukemogenic collaboration with JAK2V617F
por: Tefferi, A, et al.
Publicado: (2012)

Deregulation of apoptosis-related genes is associated with PRV1 overexpression and JAK2 V617F allele burden in Essential Thrombocythemia and Myelofibrosis
por: Tognon, Raquel, et al.
Publicado: (2012)

Expression profiles analysis identifies specific interferon-stimulated signatures as potential diagnostic and predictive indicators of JAK2V617F (+) myelofibrosis
por: Zhao, Yanhong, et al.
Publicado: (2022)

Monitoring measurable residual disease and chimerism in patients with JAK2 V617F-positive myelofibrosis after allogeneic hematopoietic cell transplantation
por: Lee, Jong-Mi, et al.
Publicado: (2023)

JAK2V617F-Positive Endothelial Cells Induce Apoptosis and Release JAK2V617F-Positive Microparticles
por: Hekimoğlu, Hilal, et al.
Publicado: (2022)

Lysyl oxidase inhibition in primary myelofibrosis: A renewed strategy
por: Piasecki, Andrew, et al.
Publicado: (2020)

Acute promyelocytic leukemia with JAK2 V617F and severe differentiation syndrome
por: Braun, Theodore P., et al.
Publicado: (2014)

MYB deregulation from a EWSR1-MYB fusion at leukemic evolution of a JAK2(V617F) positive primary myelofibrosis
por: Pierini, Tiziana, et al.
Publicado: (2016)

Coexistence of BCR/ABL1-positive chronic myeloid leukemia and JAK2 V617F-mutated myelofibrosis successfully treated with dasatinib and ruxolitinib
por: Yi, Jun Ho, et al.
Publicado: (2019)

The JAK2 V617F mutation in isolated neutropenia
por: Langabeer, Stephen E.
Publicado: (2018)

The role of the extracellular matrix in primary myelofibrosis
por: Leiva, O, et al.
Publicado: (2017)

Evading Capture by Residual Disease Monitoring: Extramedullary Manifestation of JAK2 V617F-Positive Primary Myelofibrosis After Allogeneic Stem Cell Transplantation
por: Langabeer, Stephen E., et al.
Publicado: (2015)

Prognostic significance of ASXL1, JAK2V617F mutations and JAK2V617F allele burden in Philadelphia-negative myeloproliferative neoplasms
por: Yonal-Hindilerden, Ipek, et al.
Publicado: (2015)

Anti-Glucosylsphingosine Autoimmunity, JAK2V617F-Dependent Interleukin-1β and JAK2V617F-Independent Cytokines in Myeloproliferative Neoplasms
por: Allain-Maillet, Sophie, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_c0linn95d9dijlcfg2bcif9qn0